Secondary analysis of CALGB 80802 in 129 patients with advanced HCC on sorafenib: a machine-learning signature combining CT radiomics and clinical variables predicted OS in the validation set (n=37; HR 2398; P<0.001).
Secondary analysisn = 129
Dercle et al. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)